Skip to content
Home / News |

Petros Pharmaceuticals Stock Price Doubles with 476% Sales Growth

The stock price of Petros Pharmaceuticals skyrocketed in the early hours of Wednesday’s trading, following an announcement that its STENDRA tablets have seen a 476% growth in sales year-over-year, thanks to an exclusive agreement with Hims & Hers Health Inc. 

A key provider of therapeutics for Men’s health, Petros entered an exclusive, digital health marketing partnership with Hims & Hers – a telehealth platform at the forefront of innovative, modern treatments for consumers. The erectile dysfunction tablet STENDRA saw exponential success on the platform, provoking a further expansion of the partnership via further dosage availability on the His & Hers platform. 

Fady Boctor, CCO and President of Petros stated:

WELCOME BONUS - Free Share Bundle When You Invest £50! Open a UK Investment Account: Shares, ISAs, Managed Portfolio Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply. IG
5.0
View Offers
Empfohlener Broker Multi Asset Platform
Social-Trading-Pionier mit Aktien, ETFs, Krypto und CFDs, Copy Trading inklusive. eToro
5.0
Weitere Informationen 50% of retail investor accounts lose money when trading CFDs with this provider.

“Our continued relationship with Hims supports an industry-leading telehealth platform that allows individuals to inquire about and address erectile dysfunction with discretion and by way of a convenient method of healthcare engagement,”

Adding…

“With significant growth year-over-year of STENDRA tablet sales through Hims, we are excited to expand our collaboration with Hims and enhance access to STENDRA through this critical channel.”

The data comes at a much-needed time for Petros, with the company showing a 25% loss over 2021 even with the current price spike. Consistent stock support is needed for PTPI stock to break its heavy bearish trend – PTPI is trading at $3.33, losing some momentum with a daily gain of 86%.

Should You Invest in Petros Pharmaceuticals Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

[optin-monster slug=”p0ejbloqlwcce16kx3do”]

Nigel F
Team Member

Nigels tiefes Verständnis der Finanzmärkte basiert auf über 10 Jahren Erfahrung. Nigel wurde bisher zweimal von der FCA (Financial Conduct Authority) autorisiert und hat in der letzten Zeit eine Finanz-Brokerage Firma besessen und verkauft. Er liefert hochaktuelle Analysen und Einsichten in die Finanzmärkte und in die allgemeine Wirtschafts- und Währungspolitik des Vereinigten Königreichs, der USA, Europas und Asiens.